~~<i id='952F02E983'><strike id='952F02E983'><tt id='952F02E983'><pre id='952F02E983'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：focus 2025-10-06 11:46:13 Page View：58

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NEJM study measures Covid brain fog, impact on IQ
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

leisure time

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Solving academic medical centers' existential crisis

Severalacademicmedicalcentersarereportingongoingdeficits,includingEmoryHealthcareinAtlanta.KevinC.Co

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Military medical care influenced by rank and race, new study finds

SpencerPlatt/GettyImagesHigherrankingmilitaryofficersreceivemoreresourcesandbettercarethanlowranking